Format

Send to

Choose Destination
Aliment Pharmacol Ther. 2009 Sep 15;30(6):634-42. doi: 10.1111/j.1365-2036.2009.04076.x. Epub 2009 Jun 25.

In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis.

Author information

1
Division of Gastroenterology, Department of Internal Medicine and Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA.

Abstract

BACKGROUND:

Microsatellite instability (MSI) occurs in chronically inflamed colorectal tissue and may evolve to colitis-associated cancer. In vitro data suggest that mesalazine (5-ASA) improves MSI.

AIM:

To analyse the changes in MSI in 156 distal colonic biopsies of 39 patients with ulcerative colitis that had been treated within a randomized, double-blind trial comparing 5-ASA with E. coli Nissle (EcN).

METHODS:

Two biopsies had been collected before and after 1 year of treatment. MSI testing was performed using a panel of eight markers, including 3 dinucleotide and 5 mononucleotide repeats.

RESULTS:

No MSI was observed with any of the mono-repeats, and among dinucleotide repeats, only D5S346 (maps to APC) and D17S250 (p53) were consistently informative. Overall, 31/156 (20%) biopsies displayed MSI. After 1 year, 3/11 patients displayed MSI improvement [change to microsatellite stability (MSS); 1 on 5-ASA, 2 on EcN] at D5S346 and 4/11 showed MSI worsening (change from MSS to MSI; all 5-ASA). For D17S250, the corresponding data were for 3/9 patients (2 on 5-ASA, 1 on EcN) and 2/9 (both on 5-ASA), respectively.

CONCLUSIONS:

In the set of biopsies taken from patients treated with 1.5 g 5-ASA for 1 year, there was no improvement in the prevalence of MSI in the distal colon.

PMID:
19558562
PMCID:
PMC2853877
DOI:
10.1111/j.1365-2036.2009.04076.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center